Hilde Furberg

Bio-Me is transforming microbiome analysis by making it possible to analyze hundreds of samples in less than a day, with high resolution and reproducibility and at an affordable cost. Combined with an exclusive biobank and extensive patient database, Bio-Me’s Precision Microbiome Profiling platform (PMP™) enables the development of clinical tests that will improve health and well-being worldwide.

Tappin has extensive experience in digital information and communication solutions for events and conferences. We deliver solutions for registration, digital event platform and event app - everything you need for digital, hybrid and physical events.

BerGenBio is a clinical-stage biopharmaceutical company focused on developing a pipeline of first-in-class selective AXL kinase inhibitors to treat multiple aggressive cancers. The Company is a world leader in understanding the central role of AXL kinase in promoting cancer spread, immune evasion and drug resistance – the cause of approximately 90 percent of cancer deaths. Inhibition of AXL kinase activity represents a novel approach to addressing a key mechanism in the evolution of cancer cell malignancy and aggressiveness, offering an opportunity to create important new therapeutic options for cancer patients.

Calliditas is a specialty pharmaceutical company developing high value products for patients with significant unmet medical needs. With a highly experienced, dynamic management team, Calliditas draws on its extensive experience of pharmaceutical development and marketing to efficiently identify and progress valuable and de-risked products.

Pronova is a female healthcare, specialty pharmaceutical company founded 2001 which provides unique solutions for optimal outcomes. Our unparalleled commitment best-in-class functional nutritionals with unique and often patented ingredients and dosage forms helps separate Pronova from the rest.

Navamedic is a reliable supplier of high-quality products, delivered to hospitals and through pharmacies, meeting the specific medical needs of patients and consumers. Our product portfolio consists of prescription and OTC pharmaceuticals as well as other healthcare products registered as medical nutrition, medical devices, food supplements or cosmetics. Navamedic is present in all Nordic countries, the Baltics and Benelux and has sales of specific products even in other European countries like UK and Greece. Our headquarter is in Oslo, Norway and we are listed on the Oslo Stock Exchange (ticker: NAVA). We are about 30 highly qualified employees with strong competence in regulatory affairs, quality assurance, reimbursement, marketing and sales and thus a full-service provider securing market access through our local competence.

Sedana Medical AB (publ) is a pioneer Medtech and pharmaceutical company focused on inhaled sedation to improve the patient’s life during and beyond sedation.

Herantis Pharma Plc is a clinical-stage biotechnology company developing disease modifying therapies for Parkinson’s disease. Herantis’ lead product HER-096, is an advanced small synthetic chemical peptidomimetic molecule developed based on the active site of the parent CDNF protein. It combines the compelling mechanism of action of the CDNF protein with the convenience of subcutaneous administration. The ongoing Phase 1a clinical study will assess safety, tolerability, and blood-brain barrier penetration of subcutaneously administered HER-096. Top-line data is expected by the end of 2023. The shares of Herantis are listed on the Nasdaq First North Growth Market Finland.

Bio-Me is transforming microbiome analysis by making it possible to analyze hundreds of samples in less than a day, with high resolution and reproducibility and at an affordable cost. Combined with an exclusive biobank and extensive patient database, Bio-Me’s Precision Microbiome Profiling platform (PMP™) enables the development of clinical tests that will improve health and well-being worldwide.

CombiGene’s business concept is to develop effective gene therapies for treatment of difficult-to-treat diseases for which adequate treatment methods are currently lacking. The company intends to take its candidate drugs through the phases of preclinical development and initial clinical studies under its own management, and subsequently continue development and commercialization under its own management or in collaboration with other partners. Founded on the basis of scientific discoveries made at Lund University and the University of Copenhagen, CombiGene has offices at Medicon Village in Lund, Sweden. The company is public and listed on the Swedish marketplace Nasdaq First North and the company’s Certified Advisor is FNCA Sweden AB, +46 (0)852 80 03 99 info@fnca.se . For further information, please visit www.combigene.com. CombiGene’s lead project CG01 has received funding from the European Union’s Horizon 2020 research and innovation programme